Skip to main content

Table 5 Predictors for treatment failure.

From: Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum

Treatment group Risk variables Unadjusted OR (95% CI) p-value Adjusted OR (95% CI)* p-value
SP (n = 50) Parasite density 3.74 (1.12–12.54) 0.03 3.16 (0.73–13.71) 0.13
  CIRN 4.67 (1.25–17.44) 0.02 7.21 (1.42–36.73) 0.02
  GLURP-R0 0.09 (0.02–0.41) 0.002 0.08 (0.14–0.47) 0.005
AQ (n = 50) Parasite density 0.82 (0.27–2.46) 0.72 0.77 (0.13–4.42) 0.76
  CVIET 3.55 (0.85–14.91) 0.08 2.56 (0.46–14.27) 0.28
  GLURP-R0 0.10 (0.02–0.43) 0.002 0.07 (0.01–0.48) 0.003
SP+AQ (n = 100) Parasite density 1.61 (0.74–3.47) 0.23 1.13 (0.43–2.99) 0.80
  CIRN/CVIET 3.76 (1.49–9.47) 0.005 3.44 (1.12–10.54) 0.03
  GLURP-R0 0.13 (0.06–0.33) < 0.001 0.11 (0.04–0.31) < 0.001
  1. Multivariate regression models predicting failure of antimalarial treatment. SP: sulphadoxine-pyrimethamine, AQ: amodiaquine.OR: Odds Ratio, CI: 95% Confidence interval. CIRN: Presence of the triple dhfr CIRN haplotype. CVIET: Presence of the crt CVIET haplotype. CIRN/CVIET: Presence of parasites with CIRN in patients treated with SP and presence of parasites with CVIET in patients treated with AQ. GLURP-R0: Presence of IgG antibodies to GLURP-R0. SP+AQ: Total patients in the two treatment groups. *Adjusted for age, parasite density, presence of mutant haplotypes and GLURP-R0 antibodies. No interaction between presence of mutant haplotypes and GLURP-R0 IgG antibodies was detected.